Citizen Petition from Marc Mastrana
Details
The document's own metadata, straight from the source system.
- Title
- Citizen Petition from Marc Mastrana
- Posted
- Jun 16, 2026
- Comment period
- Jun 16, 2026 – ?
- Topics
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Stance breakdown
Who commented
Breakdown by commenter type.
Comments over time
Weekly arrivals, stacked by stance.
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to browse its comments.
Issues are identified as comment analysis progresses — nothing tagged on this document yet.
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
- Jul 10, 2026Comment from Young Lung Cancer InitiativeSupportAdvocacy📎 Attachment
The Young Lung Cancer Initiative, a patient advocacy organization, supports the Citizen Petition requesting that the FDA mandate a Limitation of Use on immunotherapy labeling for NSCLC. They argue that patients with ROS1 and RET rearrangements (who are often younger) should be excluded from first-line immunotherapy to prevent ineffective treatment and ensure they receive more effective targeted therapies.
Read comment → - Jul 9, 2026Comment from Nuvation BioSupportBusiness📎 Attachment
David Hung, CEO of Nuvation Bio, supports the petition to update FDA immunotherapy labeling to exclude patients with ROS1 and RET rearrangements from first-line treatment. He argues that these updates are necessary to ensure patients receive targeted therapies that are more effective and safer than immunotherapy for these specific genetic mutations.
Read comment →